| |
ORAL Scan
|
ORAL Start
|
|---|
|
(N = 720)
|
(N = 880)
|
|---|
|
Patients with poor prognostic factor, n/N (%)
|
|
CCP+
|
600/718 (83.6)
|
737/880 (83.8)
|
|
DAS28-4(ESR) >5.1
|
635/715 (88.8)
|
822/879 (93.5)
|
|
RF+
|
546/718 (76.0)
|
726/880 (82.5)
|
|
CRP+ (>7 mg/L)
|
416/720 (57.8)
|
592/880 (67.3)
|
|
Erosion score ≥3
|
460/720 (63.9)
|
403/880 (45.8)
|
|
Baseline mTSS > mediana
|
360/720 (50.0)
|
433/880 (49.2)
|
|
Number of poor prognostic factors present at baseline, n/N (%)
|
|
≥ 1
|
719/720 (99.9)
|
878/880 (99.8)
|
|
≥ 2
|
689/720 (95.7)
|
847/880 (96.3)
|
|
≥ 3
|
627/720 (87.1)
|
780/880 (88.6)
|
|
≥ 4
|
504/720 (70.0)
|
625/880 (71.0)
|
|
≥ 5
|
315/720 (43.8)
|
368/880 (41.8)
|
|
6
|
163/720 (22.6)
|
215/880 (24.4)
|
- There were two patients in the ORAL Scan study and two patients in the ORAL Start study who had no poor prognostic factors at baseline
-
CCP cyclic citrullinated peptide, CRP C-reactive protein, DAS28-4(ESR) Disease Activity Score in 28 joints (erythrocyte sedimentation rate), mTSS van der Heijde modified total Sharp score, RF rheumatoid factor
-
aMedian baseline mTSS value was 13.1 for ORAL Scan and 4.0 for ORAL Start
